INSM - Insmed Incorporated

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $196.85 DETAILS

Stock News

Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.

Aug 27, 2026 11:26 AM • zacks.com

Insmed to Present at September 2026 Investor Conferences

BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: 12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at 8:00 a.m.

Aug 26, 2026 03:00 AM • prnewswire.com

Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal

Duquesne Family Office has beefed up its healthcare holdings.

Aug 26, 2026 02:45 AM • fool.com

Alger Mid Cap 40 ETF Q2 2026 Portfolio Review

The Alger Mid Cap 40 ETF outperformed the Russell Midcap Growth Index during the second quarter of 2026. Astera Labs, Nebius Group, and Western Digital Corporation were among the top contributors to performance. Insmed Incorporated, IREN Limited, and Erasca, Inc. were among the top detractors from performance.

Aug 25, 2026 05:20 AM • seekingalpha.com

BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— First-in-Disease and First-in-Class Therapy Approved in Japan for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — BRIDGEWATER, N.J., Aug. 24, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved BRINSUPRI ® (brensocatib 25-mg tablet), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years and older.

Aug 24, 2026 03:00 AM • prnewswire.com

Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance

Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the second quarter. The fund was underweight in the communication services, health care and consumer discretionary sectors. Strong stock selection and an overweight in IT added to relative return. Weakness in energy partially offset the favorable results.

Aug 23, 2026 10:22 AM • seekingalpha.com

Biotech Is Booming, But These 2 Stocks Missed the Memo

Biotech stocks are having one of their best stretches in years. The iShares Biotechnology ETF (NASDAQ:IBB) jumped nearly 5% Wednesday and pushed to new all-time highs, according to data from Benzinga Pro.

Aug 20, 2026 08:03 AM • benzinga.com

Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake

INSM tops Q2 revenue and earnings estimates as strong Brinsupri uptake drives a 34% stock jump and prompts sharply higher 2026 sales guidance.

Aug 07, 2026 07:41 AM • zacks.com

Insmed Q2 Earnings Call Highlights

Insmed NASDAQ: INSM reported second-quarter 2026 revenue growth driven by the continued launch of BRINSUPRI and steady sales of ARIKAYCE, while raising its full-year BRINSUPRI revenue outlook and increasing its long-term peak-sales estimates for its leading products.

Aug 06, 2026 11:05 AM • marketbeat.com

Insmed Incorporated (INSM) Q2 2026 Earnings Call Transcript

Aug 06, 2026 07:54 AM • seekingalpha.com

Insmed (INSM) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Aug 06, 2026 06:31 AM • zacks.com

Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates

Insmed (INSM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $1.7 per share a year ago.

Aug 06, 2026 05:21 AM • zacks.com

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

—Total Company Revenues of $425.5 Million for the Second Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $309.2 Million for the Second Quarter of 2026, Reflecting 49% Growth Over the First Quarter of 2026— —ARIKAYCE ® (amikacin liposome inhalation suspension) Revenues of $116.3 Million for the Second Quarter of 2026, Reflecting 8% Growth Over the Second Quarter of 2025— —Company Raises 2026 BRINSUPRI Revenue Guidance to $1.25 Billion to $1.40 Billion— —Company Reiterates 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million— —Company Raises Peak Revenue Estimate for its Three Lead Programs to More than $14 Billion Total— —Peak Revenue Estimate Consists of More than $7 Billion for BRINSUPRI, More than $6 Billion for TPIP, and More than $1 Billion for ARIKAYCE— BRIDGEWATER, N.J., Aug. 6, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

Aug 06, 2026 03:00 AM • prnewswire.com

Insmed, Inc. $INSM Stock Holdings Reduced by Bank of Nova Scotia

Bank of Nova Scotia reduced its position in Insmed, Inc. (NASDAQ: INSM) by 75.0% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,203 shares of the biopharmaceutical company's stock after selling 45,572 shares during the period. Bank of

Jul 29, 2026 12:05 AM • defenseworld.net

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.

Jul 27, 2026 09:41 AM • zacks.com

Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026

BRIDGEWATER, N.J., July 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2026 financial results on Thursday, August 6, 2026.

Jul 23, 2026 03:00 AM • prnewswire.com

Andra AP fonden Buys 41,670 Shares of Insmed, Inc. $INSM

Andra AP fonden lifted its position in shares of Insmed, Inc. (NASDAQ: INSM) by 114.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 77,970 shares of the biopharmaceutical company's stock after acquiring an additional 41,670 shares during the

Jul 22, 2026 12:03 AM • defenseworld.net

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Jul 21, 2026 03:58 AM • benzinga.com

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More

Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks got slashed and which ones earned surprise upgrades.

Jul 21, 2026 03:41 AM • 247wallst.com

Billionaire Investor Stanley Druckenmiller's Top 5 Picks: Worth Buying Today?

Stanley Druckenmiller doesn't do consensus. The Duquesne Family Office's latest 13F reveals a top-five long book that skips the mega-cap tech herd almost entirely: a Mexican discount grocer, two biotech names on wildly different trajectories, the one semiconductor stock nobody can ignore, and an Argentine oil producer sitting on a shale reserve about to unlock its first export pipeline.

Jul 20, 2026 07:36 AM • 247wallst.com